Global Intrathecal Pumps Market By Type(Baclofen, Bupivacaine, Clonidine, Morphine, Ziconotide, Others), Application-(Spasticity, Pain) By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023–2033
- Published date: Nov 2023
- Report ID: 19196
- Number of Pages: 303
- Format:
- keyboard_arrow_up
Quick Navigation
Market Overview
The Global Intrathecal Pumps Market size is expected to be worth around USD 611.0 Million by 2033 from USD 361.1 Million in 2023, growing at a CAGR of 5.4% during the forecast period from 2024 to 2033.
Intrathecal pump implants offer patients a means to alleviate debilitating pain quickly while administering minimal doses of medication, with reduced side effects and quicker therapeutic benefits than alternative forms. Their increasing popularity among those living with chronic pain in America fuels demand, as is its rising global prevalence – prompting market advancement through intrathecal pump implants intended to address such chronic conditions.
Researchers have developed intrathecal drug pumps capable of simultaneously administering multiple medications through one infusion pump. Unfortunately, using combination therapies in one reservoir may present dosing challenges due to different concentrations and administration rates for each medication. Furthermore, recalls due to battery failure or component breakage are hindering business growth; additional product modifications must ensure accurate drug administration with no errors or mistakes made along the way.
Manufacturers of intrathecal pumps have also been noted to improve their devices’ battery life. This could help reduce future surgery procedures needed to replace them. Cancer pain is on the rise due to an increased survival rate in oncologic patients. 67% of patients suffering from metastatic cancer experience pain. It is the most common symptom. Pain from chronic cancer can usually be managed using pharmacologic therapies, which include analgesia. The alternative route to analgesic administration via intrathecal drug delivery allows for the reduction of side effects while increasing bioavailability. This helps accelerate the industry’s growth.
*Actual Numbers Might Vary In The Final Report
Key Takeaways
- Market Size & Growth: Intrathecal Pumps Market size is expected to be worth around USD 611.0 Million by 2033 from USD 361.1 Million in 2023, growing at a CAGR of 5.4%
- Type Analysis: In 2023, the morphine segment was responsible for the highest revenue share at more than 32.4%.
- Application Analysis: Based on applications, the industry is further split into spasticity and pain. The pain segment dominating 71.4% market share in 2023.
- Regional Analysis: North America dominates 41.5% share and holding USD 142.1 Million market revenue in 2023.
- Technological Advantage: Technological advancements within intrathecal pump technologies such as smart systems and connectivity solutions continue to advance precision and safety of drug administration for improved patient outcomes.
- Diversification Trend: Another notable trend involves using intrathecal pumps beyond pain management in treating spasticity, movement disorders and various neurological conditions.
Type Analysis
In 2023, the morphine segment was responsible for the highest revenue share at more than 32.4%. Morphine, due to its strong receptor affinity and stability, is the best intrathecal drug administered. It also has a lot of user experience. U.S. FDA approved morphine as a long-term treatment for intrathecal pain. The side effects of long-term intrathecal opioid morphine are much less than those of systemic opioids. This will encourage the segment’s growth. Bupivacaine is forecast to grow at a 7.4% annual growth rate over the forecast period. Bupivacaine is an excellent adjunct medication for intrathecal therapy.
Multiple studies have demonstrated that bupivacaine and intrathecal opioids work together to enhance their effectiveness, contributing significantly to their rising market share. Bupivacaine can be used to help patients reduce their oral opioid intake and minimize dose escalations. Bupivacaine has many advantages that will ensure the growth of this segment. The forecast period will see significant growth in the baclofen segment. Intrathecal Baclofen is effective in the treatment of spasticity and pain. It can also be used to treat multiple types of central pain such as post-stroke and musculoskeletal.
Application Analysis
Based on applications, the industry is further split into spasticity and pain. The pain segment dominating 71.4% market share in 2023. The rising incidence of acute and chronic illnesses, including cancer that causes chronic pain, and other ailments that cause pain, including failing back syndrome, is one of the primary drivers promoting the expansion of this market. Intrathecal pumps are the best option for those with diseases that cause pain. The prevalence of spasticity will significantly rise between 2023 and 2033.
Many market players have been focusing on spasticity treatment. Medtronic’s Intrathecal Baclofen Therapy(ITB) uses Lioresal Intrathecal (baclofen), to be injected into the fluid surrounding a person’s spinal cord in order to treat severe spasticity. Globally, there are increasing stroke rates. According to a 2019 American College of Cardiology Foundation report, every 40 seconds an American experiences a stroke. Additionally, around 795,000 Americans suffer from new and recurrent strokes each year.
*Actual Numbers Might Vary In The Final Report
Key Market Segments
Type
- Baclofen
- Bupivacaine
- Clonidine
- Morphine
- Ziconotide
- Others
Application
- Spasticity
- Pain
Drivers
Rising Incidence of Chronic Pain
Chronic pain conditions have emerged as one of the primary factors fuelling growth of intrathecal pumps market. Common examples include cancer, neuropathy and other muscle-skeletal conditions which require long-term management; intrathecal pumps provide effective solution by directly administering medication to spinal cord, providing targeted relief while improving patient outcomes.
Technological Advancements
Technological advancements have been an instrumental force driving market growth. New designs of intrathecal pump technologies – such as remote monitored or programmable units – offer increased precision and safety when dispensing drugs to intrathecal sites, with enhanced features like dosage titration capabilities being widely adopted for pain management or neurological conditions.
Trends
Connectivity Solutions
A key trend in intrathecal pumps market today is the incorporation of connectivity solutions, with manufacturers turning to wireless technology to enable real-time monitoring and adjustments of pump settings in real time. Not only is this trend improving patient care by giving healthcare providers instant feedback but it is also making pain management more efficient, leading to customized treatment plans and personalized treatment strategies.
Diversified Applications
Beyond traditional pain management, researchers and manufacturers are exploring diverse applications of intrathecal pumps beyond pain relief. Researchers and manufacturers alike are investigating these pumps’ potential for treating spasticity, movement disorders and neurological conditions via drug delivery; broadening market reach by making intrathecal pumps multifaceted devices with many other uses than chronic pain relief alone.
Restraints
Initial Costs of Intrathecal Pump Systems
Initial costs associated with intrathecal pump systems act as an impediment to market growth, particularly their purchase, installation and training for healthcare facilities limiting widespread adoption and access.
Complications and Safety Concerns
Potential complications such as infections, catheter-related issues or pump malfunctions present an obstacle for market penetration of intrathecal pump therapy devices despite their proven efficacy. Healthcare providers and patients may hesitate to embrace intrathecal pump therapies due to perceived risks; impacting overall acceptance despite being proven effective devices.
Opportunities
Geographic Expansion
Broadening the geographic reach of intrathecal pump therapies presents an enormous opportunity for market expansion. Regions where chronic pain prevalence rates are high but access to advanced pain management solutions remains restricted are untapped markets that present great growth prospects for market players. Strategic initiatives designed to raise awareness, establish distribution networks and navigate regulatory frameworks may open doors of opportunity within each market player’s field of operation.
Collaboration for Holistic Solutions
Partnerships between healthcare providers, pharmaceutical companies and device manufacturers offer an opportunity for holistic pain management solutions to be developed. Integrating innovative medications with advanced pump technologies may create more holistic approaches that address patient needs more comprehensively.
Regional Analysis
North America dominates 41.5% share and holding USD 142.1 Million market revenue in 2023. The intrathecal pump market globally. The Asia Pacific is projected to grow at a 6.8% annual growth rate during the forecast period. A large patient base in the Asia Pacific will likely increase product demand. It is anticipated that intrathecal pumps will be more popular due to an increase in the number of pain management centers in India, China, and Japan. Singapore Pain Care Center, a Southeast Asian pain management center that offers an alternative to open surgery, is one example.
The growth of the region was largely due to the rising prevalence of pain-related conditions, increasing R&D spending, and the growing number of pain care centers in the U.S. & Canada. There is a growing number of cancers in the U.S., and this has created a need for more effective and sophisticated intrathecal pumps.
The American Cancer Society predicts that there will be 1.8 million new cancer cases in the US year 2020. The rising prevalence of back issues is another factor contributing to the expansion of intrathecal pumps. Approximately 80% of Americans may have back stiffness at some point in their life, as per the American Chiropractic Association. Europe is anticipated to have strong growth during the study period. Rising healthcare infrastructure spending is anticipated to boost product demand in various pain treatment facilities, which would promote regional market expansion.
*Actual Numbers Might Vary In The Final Report
Key Regions and Countries
North America
- The US
- Canada
- Mexico
Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Key Players Analysis
Strategic growth initiatives are key to gaining a competitive edge. Key companies focus on developing mergers, partnerships, product launches, and other strategic growth strategies. Flowonix Medical has received FDA approval for the Prometra II 40 ml programmable Pump for intrathecal Baclofen.
In order to keep their foothold on the global market, industry players have adopted a range of strategies including mergers & acquisitions as well as new product developments, joint ventures, and partnerships. Medtronic, for example, was granted FDA approval in January 2018 for a novel clinician program that can be used with SynchroMedTMII intrathecal drug distribution system.
Market Key Players
- Medtronic plc
- Codman & Shurtleff
- Medallion Therapeutics
- Tricumed GmbH
- Arrow International Inc.
Recent Developments
- Enhanced Drug Delivery Technologies: Researchers are making great advances in drug delivery technology with intrathecal pumps equipped with enhanced drug delivery technologies such as programmable infusion systems and targeted delivery mechanisms, to provide precise drug administration while decreasing side effects and increasing patient outcomes. These advancements aim to provide precise yet controlled drug administration while mitigating risks to patient safety.
- Wireless Connectivity and Remote Monitoring: Intrathecal pumps now incorporate wireless connectivity and remote monitoring features, enabling healthcare providers to track patient progress remotely while making necessary dosage adjustments or monitoring any complications remotely – providing patients with increased convenience while speeding timely interventions.
- Artificial Intelligence (AI) for Predictive Analytics: Artificial intelligence is being integrated into intrathecal pump systems in order to analyze patient data and predict possible issues such as catheter blockages or drug interactions that might arise; AI analytics are being utilized as part of patient treatments plans in order to optimize treatment plans and avoid complications.
- Patient-Centric Designs and User-Friendly Interfaces: Intrathecal pump manufacturers are increasingly emphasizing patient-centric designs with user-friendly interfaces to increase comfort, ease of use and compliance for intrathecal patients. Smaller pumps allow more comfortable therapy delivery while being easier for medical providers.
Report Scope
Report Features Description Market Value (2023) USD 361.1 Million Forecast Revenue (2033) USD 611.0 Million CAGR (2024-2033) 5.4% Base Year for Estimation 2023 Historic Period 2018-2022 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered By Type-(Baclofen, Bupivacaine, Clonidine, Morphine, Ziconotide, Others);Application-(Spasticity, Pain) Regional Analysis North America-US, Canada, Mexico;Europe-Germany, UK, France, Italy, Russia, Spain, Rest of Europe;APAC-China, Japan, South Korea, India, Rest of Asia-Pacific;South America-Brazil, Argentina, Rest of South America;MEA-GCC, South Africa, Israel, Rest of MEA Competitive Landscape Medtronic plc, Codman & Shurtleff, Medallion Therapeutics, Tricumed GmbH, Arrow International Inc. Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) Frequently Asked Questions (FAQ)
What is an intrathecal pump, and how does it work in pain management?An intrathecal pump is a medical device that delivers medication directly to the spinal cord area. It is used in pain management to provide targeted relief for chronic pain conditions by delivering drugs precisely to the site of action.
How big is the Intrathecal Pumps Market?The global Intrathecal Pumps Market size was estimated at USD 361.1 Million in 2023 and is expected to reach USD 611.0 Million in 2033.
What is the Intrathecal Pumps Market growth?The global Intrathecal Pumps Market is expected to grow at a compound annual growth rate of 5.4%. From 2024 To 2033
Who are the key companies/players in the Intrathecal Pumps Market?Some of the key players in the Intrathecal Pumps Markets are Medtronic plc, Codman & Shurtleff, Medallion Therapeutics, Tricumed GmbH, Arrow International Inc.
What conditions are commonly treated using intrathecal pumps?Intrathecal pumps are commonly used to manage chronic pain conditions such as cancer pain, neuropathy, and spasticity. Ongoing research explores their potential application in treating movement disorders and certain neurological conditions.
What technological advancements have been witnessed in intrathecal pump systems?Recent advancements include programmable and remotely monitored devices, as well as smart pump systems with features like connectivity solutions for real-time monitoring and adjustments. These advancements contribute to improved precision and safety in drug delivery.
What challenges hinder the widespread adoption of intrathecal pump therapies?High initial costs associated with procurement, installation, and training, as well as concerns about potential complications like infections and pump malfunctions, act as significant challenges to the broader adoption of intrathecal pump therapies.
- Medtronic plc
- Codman & Shurtleff
- Medallion Therapeutics
- Tricumed GmbH
- Arrow International Inc.
- settingsSettings
Our Clients
Single User $6,000 $3,999 USD / per unit save 24% | Multi User $8,000 $5,999 USD / per unit save 28% | Corporate User $10,000 $6,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |